|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100053411 |
|
最近更新日期: Date of Last Refreshed on: |
2022-05-17 12:01:02 |
|
注册时间: Date of Registration: |
2021-11-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
一项观察宣肺止嗽合剂治疗急性支气管炎、感染后咳嗽(风邪犯肺证)有效性及安全性的随机、安慰剂对照、双盲、多中心临床研究 |
|
Public title: |
A randomized, placebo-controlled, double-blind, and multi-center clinical study observing the efficacy and safety of Xuanfeizhisuheji for acute bronchitis and post-infection cough(syndrome of wind evil invading lung) |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
一项观察宣肺止嗽合剂治疗急性支气管炎、感染后咳嗽(风邪犯肺证)有效性及安全性的随机、安慰剂对照、双盲、多中心临床研究 |
|
Scientific title: |
A randomized, placebo-controlled, double-blind, and multi-center clinical study observing the efficacy and safety of Xuanfeizhisuheji for acute bronchitis and post-infection cough(syndrome of wind evil invading lung) |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
梁伟杰 |
研究负责人: |
张洪春 |
|
Applicant: |
Liang Weijie |
Study leader: |
Zhang Hongchun |
|
申请注册联系人电话: Applicant telephone: |
+86 10 83624052 |
研究负责人电话: Study leader's telephone: |
+86 10 84205227 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liangweijie@kangzhongshidai.com |
研究负责人电子邮件: Study leader's E-mail: |
zryygcp@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市丰台区西三环南路201号 |
研究负责人通讯地址: |
北京市朝阳区樱花园东街2号 |
|
Applicant address: |
201 Third Ring Road West, Fengtai District, Beijing |
Study leader's address: |
2 Cherry Garden Street East, Chaoyang District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京康众时代医学研究发展有限公司 |
||
|
Applicant's institution: |
Beijing Kangzhong Times Medical Research and Development Co., Ltd |
||
|
研究负责人所在单位: |
中日友好医院 |
||
|
Affiliation of the Leader: |
China-Japan Friendship Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
YW2021-006-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中日友好医院药物(器械)临床试验伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Drugs (Device) of China-Japan Friendship Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-09-23 00:00:00 |
||
|
伦理委员会联系人: |
郤思远 |
||
|
Contact Name of the ethic committee: |
Xi Siyuan |
||
|
伦理委员会联系地址: |
北京市朝阳区樱花园东街2号 |
||
|
Contact Address of the ethic committee: |
2 Cherry Garden Street East, Chaoyang District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
中日友好医院 |
||||||||||||||||||||||
|
Primary sponsor: |
China-Japan Friendship Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市朝阳区樱花园东街2号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2 Cherry Garden Street East, Chaoyang District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
甘肃普安制药股份有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Gansu Pu'an Pharmaceutical Co., Ltd |
||||||||||||||||||||||
|
Target disease: |
Acute bronchitis, cough after infection (wind evil invading lung syndrome) |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评价宣肺止嗽合剂治疗急性支气管炎、感染后咳嗽(风邪犯肺证)的有效性及安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy and safety of XuanFeiZhiSuHeJi in for acute bronchitis and Post-infection cough(wind evil invading lung syndrome). |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
急性支气管炎组纳入标准: |
||||||||||||||||||||||
|
Inclusion criteria |
Acute bronchitis group was included in the criteria: |
||||||||||||||||||||||
|
排除标准: |
急性支气管炎组排除标准: |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria for the acute bronchitis group: |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-09-30 00:00:00至 To 2022-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2021-11-22 00:00:00 至 To 2022-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由统计学专业人员提供,利用SAS9.3软件模拟产生随机数字 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Provided by statistical professionals, random numbers were simulated using SAS9.3 software |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |